Meta-hlorofenilpiperazin

Из Википедије, слободне енциклопедије
meta-Hlorofenilpiperazin
MCPP.svg
MCPP3d.png
IUPAC ime
1-(3-hlorofenil)piperazin
Klinički podaci
Način primene Oralno, nazalno, rektalno
Farmakokinetički podaci
Metabolizam Hepatic
Poluvreme eliminacije 2-6 sata
Izlučivanje Renalno
Identifikatori
CAS broj 6640-24-0 ДаY
ATC kod none
PubChem CID 1355
IUPHAR/BPS 142
ChemSpider 1314 ДаY
ChEBI CHEBI:10588 ДаY
ChEMBL CHEMBL478 ДаY
Hemijski podaci
Formula C10H13ClN2
Molarna masa 196,676 g/mol
  (verify)

meta-Hlorofenilpiperazin (mCPP) je psihoaktivni lek iz fenilpiperazinske klase. On je razvijen krajem 1970-tih i korišten je u naučnim istraživanjima, pre nego što je postao dezijnirana droga sredinom 2000-tih.[1][2] mCPP je detektovan u pilulama koje su reklamirane kao legalne alternative za nedopuštne stimulanse u Novom Zelandu i u pilulama koje su prodavane kao "ekstazi" u Evropi i Sjedinjenim Državama.[3][4]

Uprkos pokušaja da se uvede u upotrebu kao rekreaciona supstanca, mCPP se zapravo generalno smatra nepoželjnim jer proizvodi neprijatna iskustva.[3] Njemu nedostaju potkrepljujući efekti,[5] proizvodi depresivne i anksiogene efekte kod glodara i ljudi,[6][7] i može da indukuje panične napade kod osoba koje su im podložne.[8][9][10][11] On takođe pogoršava opsesivno-kompulzivne simptome kod ljudi sa tim poremećajem.[12][13][14]

Vidi još[уреди]

References[уреди]

  1. Bossong MG, Van Dijk JP, Niesink RJ (2005). „Methylone and mCPP, two new drugs of abuse?”. Addiction Biology. 10 (4): 321—3. PMID 16318952. doi:10.1080/13556210500350794. 
  2. Lecompte Y, Evrard I, Arditti J (2006). „[Metachlorophenylpiperazine (mCPP): a new designer drug]”. Thérapie (на језику: French). 61 (6): 523—30. PMID 17348609. 
  3. 3,0 3,1 Bossong M; Brunt T; Van Dijk J; et al. (2009). „mCPP: an undesired addition to the ecstasy market”. Journal of Psychopharmacology (Oxford, England). 24 (9): 1395—401. PMID 19304863. doi:10.1177/0269881109102541. 
  4. Vogels N, Brunt TM, Rigter S, van Dijk P, Vervaeke H, Niesink RJ (2009). „Content of ecstasy in the Netherlands: 1993-2008”. Addiction (Abingdon, England). 104 (12): 2057—66. PMID 19804461. doi:10.1111/j.1360-0443.2009.02707.x. 
  5. Tancer M, Johanson CE (2003). „Reinforcing, subjective, and physiological effects of MDMA in humans: a comparison with d-amphetamine and mCPP”. Drug and Alcohol Dependence. 72 (1): 33—44. PMID 14563541. doi:10.1016/S0376-8716(03)00172-8. 
  6. Rajkumar R, Pandey DK, Mahesh R, Radha R (2009). „1-(m-Chlorophenyl)piperazine induces depressogenic-like behaviour in rodents by stimulating the neuronal 5-HT(2A) receptors: proposal of a modified rodent antidepressant assay”. European Journal of Pharmacology. 608 (1-3): 32—41. PMID 19269287. doi:10.1016/j.ejphar.2009.02.041. 
  7. Kennett GA, Whitton P, Shah K, Curzon G (1989). „Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists”. European Journal of Pharmacology. 164 (3): 445—54. PMID 2767117. doi:10.1016/0014-2999(89)90252-5. 
  8. Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991). „Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects”. Biological Psychiatry. 30 (10): 973—84. PMID 1756202. doi:10.1016/0006-3223(91)90119-7. 
  9. Charney DS, Woods SW, Goodman WK, Heninger GR (1987). „Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects”. Psychopharmacology. 92 (1): 14—24. PMID 3110824. 
  10. Van Veen JF, Van der Wee NJ, Fiselier J, Van Vliet IM, Westenberg HG (2007). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) in patients with generalized social anxiety disorder, panic disorder and healthy controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 17 (10): 637—42. PMID 17481859. doi:10.1016/j.euroneuro.2007.03.005. 
  11. van der Wee NJ, Fiselier J, van Megen HJ, Westenberg HG (2004). „Behavioural effects of rapid intravenous administration of meta-chlorophenylpiperazine in patients with panic disorder and controls”. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology. 14 (5): 413—7. PMID 15336303. doi:10.1016/j.euroneuro.2004.01.001. 
  12. Hollander E; DeCaria CM; Nitescu A; et al. (1992). „Serotonergic function in obsessive-compulsive disorder. Behavioral and neuroendocrine responses to oral m-chlorophenylpiperazine and fenfluramine in patients and healthy volunteers”. Archives of General Psychiatry. 49 (1): 21—8. PMID 1728249. 
  13. Broocks A; Pigott TA; Hill JL; et al. (1998). „Acute intravenous administration of ondansetron and m-CPP, alone and in combination, in patients with obsessive-compulsive disorder (OCD): behavioral and biological results”. Psychiatry Research. 79 (1): 11—20. PMID 9676822. doi:10.1016/S0165-1781(98)00029-8. 
  14. Pigott TA; Zohar J; Hill JL; et al. (1991). „Metergoline blocks the behavioral and neuroendocrine effects of orally administered m-chlorophenylpiperazine in patients with obsessive-compulsive disorder”. Biological Psychiatry. 29 (5): 418—26. PMID 2018816. doi:10.1016/0006-3223(91)90264-M. 

Spoljašnje veze[уреди]